We conducted a nation-wide survey of 112 adult Japanese patients who underwent reduced-intensity stem cell transplantation (RIST) from 1999 to 2002. Underlying diseases included indolent (n ¼ 45), aggressive (n ¼ 58) and highly aggressive lymphomas (n ¼ 9). Median age of the patients was 49 years. A total of 40 patients (36%) had relapsed diseases after autologous stem cell transplantation and 36 patients (32%) had received radiotherapy. RIST regimens were fludarabine-based (n ¼ 95), low-dose total body irradiation-based (n ¼ 6) and others (n ¼ 11). Cumulative incidences of grade II-IV acute graft-versus-host disease (GVHD) and chronic GVHD were, respectively, 49 and 59%. Cumulative incidences of progression and progression-free mortality were 18 and 25%, respectively. With a median follow-up of 23.9 months, 3-year overall survival rates were 59%. A multivariate analysis identified three significant factors for progression, which are history of radiation (relative risk (RR) 3.45, confidential interval (CI) 1.12-10.0, P ¼ 0.03), central nervous system involvement (RR 6.25, CI 2.08-20.0, P ¼ 0.001) and development of GVHD (RR 0.28, CI 0.090-0.86, P ¼ 0.026). RIST may have decreased the rate of transplant-related mortality, and GVHD may have induced a graft-versuslymphoma effect. However, whether or not these potential benefits can be directly translated into improved patient survival should be evaluated in further studies. Keywords: graft-versus-host disease; graft-versus-lymphoma effect; nonmyeloablative hematopoietic stem cell transplantation; indolent lymphoma; aggressive lymphoma Allogeneic stem cell transplantation (allo-SCT) is a curative treatment for advanced malignant lymphoma.
phoma effect; nonmyeloablative hematopoietic stem cell transplantation; indolent lymphoma; aggressive lymphoma Allogeneic stem cell transplantation (allo-SCT) is a curative treatment for advanced malignant lymphoma. 1, 2 Initially, the benefit of allo-SCT was thought to be largely dependent on the intensity of the conditioning regimen prior to transplantation. Recently, an additional benefit of allo-SCT is derived from an allogeneic graft-versus-malignancy (GVM) effect that reduces the likelihood of disease relapse following transplantation. [3] [4] [5] [6] With high regimen-related toxicity (RRT) and treatment-related mortality (TRM), high-intensity, myeloablative conditioning regimens are being replaced by reduced-intensity or nonmyeloablative conditioning regimens. The preliminary data suggest improved survival rates due to decreased TRM. 7 Reduced-intensity stem cell transplantation (RIST) is potentially a curative treatment for heavily pretreated, elderly patients; however, little information is available regarding the outcomes of RIST for malignant lymphoma. We retrospectively analyzed the outcome of RIST. The purpose of this study was to elucidate the treatment-related toxicity of RIST and to evaluate the impact of a potential graftversus-lymphoma (GVL) effect.
Patients and methods

Data collection
We conducted a nation-wide retrospective survey of 112 adult Japanese patients who underwent RIST from 1999 to 2002 in 32 participating hospitals. All of the RIST recipients who were eligible in this study were included in each hospital. In Japan, approximately 2000 transplants are performed annually. The types of transplantation are autologous (40%), myeloablative allogeneic (45%), and reduced-intensity or nonmyeloablative allogeneic transplantation (15%). 8 Since 20% of RIST recipients had advanced malignant lymphoma, 8 approximately half of the patients with malignant lymphoma who underwent RIST in Japan were surveyed in this study.
Data were derived from questionnaires distributed to each participating center. Minimum data required for the inclusion of a patient in this study were age, histological diagnosis, prior treatment details, status at transplant, conditioning regimens, date of transplant, date of last follow-up, disease status at last follow-up, date of disease progression/death and causes of death. Information on rituximab use prior to RIST was not collected in this study.
Definition
Reduced-intensity regimens were defined as reported previously. 9, 10 The upper limits of busulfan, melphalan, and TBI were 8 mg/kg, 140 mg/m 2 , and 2 Gy, respectively, for consideration as reduced-intensity preparative regimens. Engraftment was defined as white blood cell counts 41.0 Â 10 9 /l or absolute neutrophil counts 40.5 Â 10 9 /l for two consecutive days. Graft-versus-host-disease (GVHD) was clinically diagnosed in combination with skin or gut biopsies. Acute and chronic GVHD were graded according to the established criteria. 11, 12 Histological diagnosis was based on institutional diagnosis. Discrepancies in nomenclature among centers were resolved according to the synonyms in the WHO classification. 13 Indolent, aggressive, and highly aggressive lymphomas were classified according to the report by Chan 14 with some modifications. Transformed low-grade lymphoma was classified into aggressive lymphoma. However, patients who had recurrent low-grade lymphoma rarely receive biopsy before transplant, and patients with transformed low-grade lymphoma might have been analyzed as lowgrade lymphoma in this study. Adult T-cell leukemia/ lymphoma was classified into a highly aggressive category, because its clinical course is aggressive and patients' median survival is as short as about 6 months. Chimerism was determined by short-tandem repeat PCR method or sex chromosome FISH, and disease status was evaluated with CT, MRI scan, bone marrow aspiration, or spinal tap in varying intervals from 1 month to 60 months according to each participating hospital's rule. Those with chemosensitive diseases included all patients who had shown a response to the last therapy prior to transplantation (partial remission (PR), complete remission (CR) unconfirmed, and CR); all the other patients were classified as having chemoresistant diseases. Progression-free survival (PFS) was measured as the time from the day of transplantation until disease relapse/progression or death from any causes. Both relapse and progression were defined as disease progression with transplantation-related deaths being censored. TRM is defined as all causes of deaths without disease progression at any time after transplant. RRT was defined as all nonhematological organ dysfunctions from day 0 to day 28, and were graded according to the Seattle criteria. 15 
Statistical analysis
The primary end point was 3-year PFS. Secondary end points included 3-year overall survival (OS), TRM, and disease progression rates. The cumulative incidences of progression and progression-free mortality were evaluated using the Gray's method, 16 considering each other's risk as a competing risk. OS and PFS were estimated using the Kaplan-Meier method. Potential confounding factors considered in the analysis were age, sex, donor types (an HLA-matched related donor and an alternative donor), stem cell sources (marrow, peripheral blood, and cord blood), performance status according to the Eastern Cooperative Oncology Group (ECOG) criteria, 17 serum levels of lactate dehydrogenase, intervals from diagnosis to transplantation, the number of prior chemotherapy regimens, history of autologous SCT, history of radiation, clinical stages, chemosensitivity, presence of extramedullary involvement (central nervous system, and marrow), presence of bulky mass, disease category (indolent, aggressive, highly aggressive), different conditioning regimens, and use of methotrexate as GVHD prophylaxis. Proportional hazard modeling was used to evaluate the influence of these factors on PFS and disease progression. The influence of the development of GVHD on PFS and disease progression was evaluated using the proportional hazard modeling treating the development of acute GVHD as a time-dependent covariate. Factors associated with at least borderline significance (Po0.10) in a univariate analysis were subjected to a multivariate analysis using backward stepwise proportional-hazard modeling. P-values of less than 0.05 were considered statistically significant.
Results
Patient characteristics and transplantation procedures
Patients' characteristics and transplantation procedures are shown in Table 1 . None received ex vivo T-cell depleted transplantation.
Regimen-related toxicity
Information on RRT within 28 days of RIST was available in 106 patients and was graded according to Bearman's criteria (Table 2) .
Engraftment
Four patients died before engraftment. None developed primary graft failure. Of the 108 patients who achieved primary engraftment, 91 patients were evaluable for chimerism. In all, 85 patients (93%) achieved complete donor-type chimerism within 100 days of transplant. Three subsequently achieved complete donor-type chimerism, one died of infection with mixed chimerism 164 days after transplant, and two remained alive with mixed chimerism (623 and 606 days after transplant). None received donor lymphocyte infusion (DLI) for engraftment.
Graft-versus-host disease
Seven patients were not evaluated for acute GVHD, since four died before engraftment and three lacked the data regarding GVHD. In the remaining 105 patients, cumulative incidence of grade II-IV acute GVHD was 49% with a median onset of day 24 (range, . Of the 98 patients survived longer than 100 days after transplant, cumulative incidence of chronic GVHD was 59%.
Response to RIST
In all, 84 patients including 52 patients with chemosensitive diseases and 32 patients with chemoresistant diseases had measurable lesions prior to transplant, and were evaluated for response to RIST. A total of 72 patients (86%) responded to RIST (CR 63 and PR nine). As of February 2004, median duration of response was 22.5 months (range, 2.2-38.9). After initial response to RIST, primary disease recurred or progressed in four patients. Median interval between initial response and disease progression was 4.1 months (range, 1.4-11.2). Response to RIST was shown according to histological subtypes (Table 3 ). Five patients Blood from an HLA-mismatched related donor 3 5 Marrow from an HLA-matched related donor 1 5 Mismatched cord blood 0 6
HDT/ASCT ¼ high-dose therapy and autologous stem cell transplantation; CR ¼ complete remission; ND ¼ not described; LDH ¼ lactate dehydrogenase; GVHD ¼ graft-versus-host disease. a Indolent lymphoma included follicular (n ¼ 44), marginal zone B-cell (n ¼ 2), small lymphocytic (n ¼ 1), lymphoplasmacytic (n ¼ 1), and cuta-
, anaplastic large cell (n ¼ 4), and angioimmunoblastic (n ¼ 2). Transformed low-grade lymphoma was treated as diffuse large B-cell lymphoma (n ¼ 4). d Normal ranges of LDH were determined in each participating hospital. received DLI for either disease progression or disease persistence following RIST. One showed objective disease response after DLI. The outcome in patients with CNS disease or whether they relapse in the CNS or outside the CNS was not collected.
OS, PFS and TRM
As of February 2004, 69 were alive with a median follow-up duration of 23.9 months (range, 3.4-44.5). The 3-year OS and PFS were 59.0% (95% CI, 55.0-64.0%) and 56.5% (95% CI, 51.5-61.5%), respectively ( Figure 1 ). The 3-year OS according to the histological subtypes ( Figure 2 ) was indolent 79% (95% CI, 67-91%), aggressive 48% (95% CI, 35-61%), and highly aggressive 0%; follicular 81% (95% CI, 69-92%), diffuse large B-cell 31% (95% CI, 13-49%), peripheral T-cell 56% (95% CI, 23-89%), and mantle cell 76% (95% CI, 45-100%). There was no difference in 3-year OS between T-cell and B-cell lymphomas (P ¼ 0.08). The cumulative incidences of progression and progression-free mortality were 18.3 and 25.2%, respectively ( Figure 3) . Since progression-free mortality was evaluated with relapse censored as a competing risk, it is apparently lower than an absolute incidence of 27%. Primary causes of death were disease progression in 13, whereas 30 died without disease progression (Table 3) GVHD complicated with infection (n ¼ 15), infection (n ¼ 13), idiopathic pneumonia syndrome (n ¼ 1), and hepatic veno-occlusive disease (n ¼ 1). The causative organisms included Gram negative rods (n ¼ 4), Gram positive cocci (n ¼ 4), fungi (n ¼ 3), and unknown (n ¼ 2).
Prognostic factors for PFS
Results of univariate and multivariate analysis on relapse and PFS are shown in Tables 4 and 5 , respectively. Three variables including history of any types of irradiation prior to RIST, CNS involvement at transplant, and absence of grade II-IV acute GVHD were adversely associated with disease progression (Table 4) . Four variables including poor PS, short interval from diagnosis to transplant, nonmethotrexate-containing GVHD prophylaxis, aggressive-type histology were adversely associated with PFS (Table 5 ).
Discussion
Although the eligibility was decided according to different protocols at each participating hospital and the possibility of a selection bias cannot be excluded, this multicenter, retrospective analysis described the gross characteristics of RIST in Japan.
RRT has been a significant problem in allo-SCT for malignant lymphoma, [18] [19] [20] while only two patients (1.8%) died of RRT within 28 days of RIST. TRM was lower than those reported on conventional allo-SCT. [18] [19] [20] RIST might decrease RRT and provided better prognosis in short-term follow-up than conventional transplantation. The incidence of acute GVHD is lower in Japan than in Western countries because of the relative genetic homogeneity of the population; 21 however, 43 patients developed grade II to IV acute GVHD, which was fatal in 15 patients. The rate of acute GVHD was similar to those reported on myeloablative or reduced-intensity allo-SCT from Western countries. 19, 20, 22, 23 The relatively high incidence of acute GVHD in the present study was probably associated with less intense GVHD prophylaxis in RIST than in conventional allo-SCT. The use of methotrexate beneficially affected PFS in our multivariate analysis. Additional methotrexate is probably beneficial especially in RIST because RIST recipients are elderly and with comorbidities, and GVHD is a higher risk of TRM.
A GVL effect is associated with GVHD in allo-SCT for hematologic malignancies. 3, 24 While this trend is remarkable in acute leukemia, 3 it has been inconsistent in malignant lymphoma. 4, 18, 20, 25 GVHD was associated with reduced disease progression; however, PFS was not improved in the present study. GVHD is sometimes fatal, and may offset patients' prognosis. Since the impact of GVHD on a GVL effect varies according to disease status and patients' conditions, management of GVHD should be tailored. Further studies are warranted to establish a proper GVHD prophylaxis.
Few reports are available on infections after RIST. [26] [27] [28] [29] RIST seemed to be associated with less infections due to the shorter duration of neutropenia and less damage to mucosal barriers. However, we showed that opportunistic infection is the second leading cause of death in RIST. Most patients had received multiple courses of chemotherapy, and occult infections might have existed at RIST. These infections can be fatal in RIST recipients. Management of bacterial and fungal infections following RIST requires further investigation.
In the present study, PFS was significantly different according to histological subtypes (Figure 2) , which is consistent with previous reports. 23, 30 Indolent lymphoma has a low relapse rate, and the major causes of mortality are GVHD and infections (Table 3 ). Our study showed that chemotherapy-resistant indolent lymphoma can achieve good outcomes after RIST, and that the response to RIST is not associated with chemosensitivity before RIST ( Table 3 ). These findings are comparable to previous reports. 19 RIST for indolent lymphoma needs to be reserved for those with advanced diseases, since RIST is associated with TRM. Intensification of GVHD prophylaxis and infection control may produce more promising results in RIST for indolent lymphoma.
In contrast, the outcomes of RIST for aggressive and highly aggressive lymphomas were poor. 23 Although allo-SCT has been considered ineffective for these lymphomas, 30 the present study showed that some can achieve remission after RIST (Table 3) . However, the response rate of these lymphomas was not satisfactory in RIST for chemorefractory aggressive and highly aggressive lymphomas. Investigations are necessary to determine better timing and indications of RIST for these lymphomas. This study and others 31 revealed history of irradiation, central nervous system involvement and chemosensitivity at transplantation as significant prognostic factors (Table 4) . These are useful to identify patients who would benefit from RIST. Another approach to improve the response rates of RIST for these lymphomas is intensification of preparative regimens as far as patients can tolerate without increasing RRT. Since the strength of GVL effect depends on the initial ratio between the number of tumor-specific immunocompetent cells in the graft and tumor cell burden of the recipient, 32 debulking of lymphoma cells by preparative regimens will be beneficial. The other problem in RIST for aggressive and highly aggressive lymphoma is the high rates of TRM. Most patients who achieved response after RIST remained progression-free (Table 3) , suggesting a benefit of allogeneic immunity to suppress disease progression. Intensification of GVHD prophylaxis contributes to improve GVHD-related outcomes; [33] [34] [35] however, use of potent immunosuppressive agents might diminish a GVL effect, 35 and could increase the rate of serious infections. 34 Maintaining the fine balance between GVHD and GVL effects is important and frequently difficult in RIST for these lymphomas. Another promising approach is to reinforce a GVL effect without increasing GVHD. For example, monoclonal antibodies such as rituximab, tumor vaccines, and adoptive transfer of cytotoxic T-cells targeting minor histocompatibility antigens or tumorspecific antigens have been investigated.
36-38
The risk of progression was significantly higher among patients with prior history of local radiation therapy (RT) than those who did not received RT (Table 4) . RT is indicated when the patients have chemo-refractory disease, central nervous system involvement or bulky mass, which means that patients with a history of RT carry risk factors of poor outcomes.
The survival of patients with PS 0-1 was significantly longer than that with PS 2-4 ( Table 5 ). PS is affected by age, infections, and aggressiveness of the diseases, and patients with poor PS carry the overlapping risk factors of poor outcomes. While RIST is considered feasible even for patients with worse PS than is conventional stem-cell transplantation, the present study showed that the poor PS is also a risk factor of poor RIST outcomes. The time from diagnosis to RIST also affected the outcomes; our univariate and multivariate analyses showed significant differences in PFS. The observations are comparable to the results by van Besien. 18 While the present study provided novel information on RIST for advanced lymphoma, we need to take its limitations into consideration. It is a small-sized, retrospective study; unrecognized biases might have affected the results. However, it demonstrated that many patients with advanced lymphoma can survive after RIST. These observations provide a rationale for continuing our clinical trials on RIST for malignant lymphoma, focusing on minimizing toxicities, preventing GVHD, and controlling infectious complications. It is imperative to establish optimal preparative regimens and management of GVHD to enhance a GVL effect and to reduce TRM. Although the present study showed that patients with chemotherapyresistant indolent lymphoma can achieve durable remission after RIST, we cannot yet conclude that RIST improves the prognosis. Despite progressive improvement of safety, the risk of significant TRM limits the widespread application of allo-SCT for malignant lymphoma. Without evidence of efficacy, most physicians considered this risk too high to justify studies of allo-SCT. Phase III clinical trials comparing RIST with standard chemotherapy are warranted. However, these trials are frequently problematic, considering that therapeutic approaches are different between transplant and chemotherapy, and that the standard therapies for some subtypes such as mantle cell and peripheral T-cell lymphoma are dismal. Registry multicenter data such as in this study will allow for a reasonable analysis of the role of RIST in advanced lymphoma. 
